Camargo Invests in High-Level IT System To Increase Accessibility and Preserve Client Data

Camargo Invests in High-Level IT System To Increase Accessibility and Preserve Client Data

January 30, 2014

CINCINNATI--()--Camargo Pharmaceutical Services recently completed an extensive IT system update to offer its clients improved data availability, security, storage and redundancy. The new system is an important investment to Camargo's infrastructure, allowing the full-service development partner to add value for its clients.

With these improvements, Camargo provides each of its national and international clients with an individual website including large-scale data storage availability, document management with version control, a superior level of security with minimal interruptions and 24/7 rapid access. The system also includes data retention and preservation for at least 20 years — exceeding the FDA's and global regulatory agencies' minimum data preservation requirements.

"Implementing enhanced data access and storage capacity are examples of the strides Camargo is making to broaden our service line, support our clients from concept through commercialization and grow our client base internationally," said Jim Beach, chief operating officer for Camargo. "Data and its preservation are the lifeblood of product development programs and this new system supports our critical role as stewards of our clients' data."

To learn more about Camargo's service offerings, visit camargopharma.com.

About Camargo Pharmaceutical Services

Camargo Pharmaceutical Services is your full-service drug development partner specializing in the 505(b)(2) process. Before development even begins, we verify profit potential by working with your team to develop a comprehensive program and timeline complete with important milestones and cost objectives. We manage every facet of the plan throughout your development continuum, from feasibility assessments, formulation and testing the drug product, to conducting preclinical and clinical studies, to final submission. Connect with Camargo on LinkedIn, the President's blog or visit www.camargopharma.com for more information.

Contacts

SCORR Marketing
Lea Studer, +1 308-237-5567
[email protected]

 

Suggested Articles

There's no evidence personal patient information leaked during the 11-week breach, but the same can't be said about Sangamo's own secrets.

Through a new online tracker, AllTrials names sponsors who fail to report clinical trial results on time per the FDAAA Final Rule.

The new solution aims to streamline the incorporation of human genomic data into clinical trial designs.